Physician profile
Andrew Antoszyk
NPI 1427016443
$5,056.08
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,498 · 2020: $1,626 · 2021: $273 · 2022: $659.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Genentech, INC. | $1,542.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $826.41 | 2019-2020 | |
| Notal Vision, INC. | $568.19 | 2022 | |
| Genentech USA, INC. | $192.34 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $122.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.07 | 2019 | |
| Apellis Pharmaceuticals, INC. | $34.03 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.24 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $20.52 | 2021 | |
| Abbvie INC. | $20.34 | 2022 | |
| Alimera Sciences, INC. | $15.50 | 2022 | |
| Spark Therapeutics, INC. | $13.69 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$9,998.80 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Antoszyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.